Your search for colorectal cancer matches 706 pages

Showing 101 - 150


colorectal cancer

Most Patients Undergoing Elective Colorectal Surgery Receive Inadequate Bowel Preparation to Prevent Postoperative Complications

In the largest study of its kind to date, researchers from Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University confirmed that oral antibiotics combined with mechanical bowel preparation were more effective at preventing surgical site infections...

colorectal cancer

ASCP/CAP/AMP/ASCO Clinical Practice Guideline Focuses on Molecular Biomarker Testing for Patients With Colorectal Cancer

A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes. The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for...

Pancreatic Cancer
Gastrointestinal Cancer
Colorectal Cancer

‘Collateral Lethality’ May Offer New Therapeutic Approach to Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for the development of therapies for several cancers. Scientists at The University of Texas MD...

colorectal cancer
lung cancer

Potential Suboptimal Use of Guideline-Endorsed Genomic Testing in Non–Small Cell Lung and Colorectal Cancers

In a study reported in the Journal of Oncology Practice, Gray et al found that many medical oncologists did not use genomic testing endorsed by guidelines in place in 2012 and 2013 in patients with non–small cell lung cancer (NSCLC) and colorectal cancer. The study involved a survey of U.S....

Colorectal Cancer

Expert Point of View: Frank A. Sinicrope, MD

Frank A. Sinicrope, MD, Professor of Medicine and Oncology at the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that the regimen of irinotecan/cetuximab (Erbitux)/­vemurafenib (Zelboraf) could be an important approach to treating this challenging tumor subtype. “BRAF-mutated tumors have a...

Colorectal Cancer

Dual Inhibition Proves Effective for BRAF-Mutated Colorectal Tumors

In patients with metastatic colorectal cancer who have mutations in BRAF V600, the addition of the BRAF inhibitor vemurafenib (Zelboraf) to cetuximab ­(Erbitux) and irinotecan significantly improved progression-free survival, results of the phase II Southwest Oncology Group (SWOG) 1406 trial have...

colorectal cancer

Postmenopausal Normal-Weight Women With Poor Metabolic Health May Have Higher Risk for Colorectal Cancer

Few studies have explored the association between metabolic phenotype and colorectal cancer incidence in normal-weight individuals. Now, a study comparing the risk of colorectal cancer in normal-weight postmenopausal women with a metabolically unhealthy phenotype vs those with a metabolically...

colorectal cancer

Cynthia L. Sears, MD, on Colon Cancer: Keynote Lecture

Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.

colorectal cancer

Brendan J. Guercio, MD, on Colorectal Cancer and Physical Activity: Impact on Survival

Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).

colorectal cancer

Cornelis van de Velde, MD, PhD, on Rectal Cancer: A Database Update

Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521). For More Information: www.IWWD.org

colorectal cancer

Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).

colorectal cancer

Cathy Eng, MD, on Anal Squamous Cell Cancer: Management Strategies

Cathy Eng, MD, of The University of Texas MD Anderson Cancer Center, discusses management approaches to anal cancer, including the current standard of care, as well as novel approaches for locally advanced and metastatic disease.

colorectal cancer

Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).

colorectal cancer

2017 GI Cancers Symposium: Less Than Half of Recommended Adults Screened for Lynch Syndrome

A team of researchers at Fox Chase Cancer Center found that, despite the recommendation of screening guidelines, less than half of adults younger than 50 years old who have colorectal cancer are being screened for Lynch syndrome, a genetic anomaly that increases the risk of colorectal and several...

colorectal cancer

Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer

In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...

colorectal cancer

2017 GI Cancers Symposium: Watch-and-Wait Approach for Rectal Cancer Appears an Option for More Patients

Real-world data from a large observational study suggests that omitting surgery in strictly selected patients with a clinical complete response does not compromise outcomes in rectal cancer. The 3-year survival rate among patients who received “watch-and-wait” care after initial cancer...

colorectal cancer

2017 GI Cancers Symposium: Physical Activity May Be Linked to Longer Survival in Advanced Colorectal Cancer

A new analysis of the CALGB 80405 (Alliance) trial suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active. In a large clinical trial, patients who at the time of starting chemotherapy reported engaging in physical activity...

breast cancer
colorectal cancer
issues in oncology

Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?

Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study published by Cooper et al in Cancer looked at how the Affordable Care Act (ACA), which eliminated such out-of-pocket...

colorectal cancer

Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer

In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. The study involved 450 patients diagnosed with colorectal cancer at age < 50...

Colorectal Cancer

Colonoscopy Screening in Older Adults

A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found...

colorectal cancer

T-Cell Transfer Therapy Targets Mutant KRAS in Metastatic Colorectal Cancer

In a case report in The New England Journal of Medicine, Tran et al at the National Cancer Institute describe response to adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes containing T cells targeting personalized cancer neoepitopes in a patient with lung metastases from...

Issues in Oncology
Lung Cancer
Gastrointestinal Cancer
Prostate Cancer
Colorectal Cancer

At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints

The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...

colorectal cancer

Blocking ADAM17 Protein May Help to Circumvent Resistance to Cetuximab in Bowel Cancer

Blocking a molecule may bypass bowel cancer's defense against the drug cetuximab, according to new research presented by Weir et al at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, United Kingdom. Cetuximab is used to treat advanced bowel cancer, and just under half ...

Colorectal Cancer

New Blood Test for Colorectal Cancer Recurrence: Twice as Sensitive as CEA Test

In a new report published by Young et al in Cancer Medicine,1 a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard-of-care...

colorectal cancer

Study Shows International Trends in Anal Cancer Incidence Rates

A new American Cancer Society study finds that incidence of anal cancer has been increasing in women or in both men and women in 13 of 18 countries studied, particularly in the Americas, Northern/Western Europe, and Australia. The authors say population-based preventive measures, including human...

colorectal cancer

New Blood Test for Colorectal Cancer Recurrence Is Twice as Sensitive as CEA Test

In a new report published by Young et al in Cancer Medicine, a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer (CRC) recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard of...

colorectal cancer

Effect of Isolated Peritoneal and Nonperitoneal Metastasis and Metastatic Sites on Survival in Patients With Colorectal Cancer

Overall survival was poorer with isolated peritoneal metastasis in colorectal cancer vs other isolated sites of metastasis in patients receiving first-line systemic therapy but similar to that in patients with peritoneal plus another metastatic site and in patients with at least two nonperitoneal...

colorectal cancer

ESMO 2016: Longer Interval Between Preoperative Chemoradiotherapy and Surgery Urged in Locally Advanced Rectal Cancer

A longer waiting interval from the end of preoperative chemoradiotherapy to surgery increases the rate of pathologic complete response and yields a higher proportion of patients achieving tumor downstaging in patients with locally advanced rectal cancer, according to new findings from a...

colorectal cancer

ESMO 2016: Dabrafenib/Trametinib/Panitumumab Improves Efficacy in BRAF Mutation–Positive Metastatic Colorectal Cancer

Patients with metastatic colorectal cancer and tumors harboring the BRAF V600E mutation who received triple therapy with dabrafenib (Tafinlar), trametinib (Mekinist), and panitumumab (Vectibix) showed an improved best overall response and prolonged progression-free survival compared to...

colorectal cancer

Massachusetts Health Insurance Expansion Associated With Increased Resection and Reduced Emergent Resection for Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Loehrer et al found that the 2006 Massachusetts health-care reform has resulted in increased rates of resection and reduced emergent resection for colorectal cancer. The study used the Hospital Cost and Utilization Project State Inpatient...

colorectal cancer

ESMO 2016: Nintedanib Improves Progression-Free Survival but Not Overall Survival in Metastatic Colorectal Cancer

Nintedanib (Ofev) improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to the results of the phase III LUME-colon 1 trial presented by Van Cutsem et al at the 2016 European Society of...

colorectal cancer

Derek J. Jonker, MD, on Colorectal Cancer: Results From the CCTG/AGITG CO.23 Trial

Derek J. Jonker, MD, of The Ottawa Hospital Cancer Centre, discusses phase III study findings on napabucasin vs placebo in patients with pretreated advanced colorectal cancer. (Abstract 454O)

colorectal cancer

Heinz-Josef Lenz, MD, on Colon Cancer: Sidedness and Treatment Update

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the importance of tumor location, and its implications for treatment, in right-sided and left-sided metastatic colon cancer.

colorectal cancer

Sian A. Pugh, MBBS, on Colorectal Cancer: Long-Term Results of the FACS Trial

Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)

colorectal cancer

Does Adding Adjuvant Bevacizumab to Capecitabine Benefit Patients With Colorectal Cancer?

Kerr et al found that adding adjuvant bevacizumab (Avastin) to capecitabine did not improve disease-free survival in unselected patients with stage III or high-risk stage II colorectal cancer. The results of the phase III QUASAR 2 trial were reported in The Lancet Oncology. Study Details In the...

colorectal cancer

Does Colonoscopy Screening in Older Adults Prevent Colorectal Cancer?

A large population-based observational study by García-Albéniz et al evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found the test reaped only a modest benefit in preventing colorectal...

Colorectal Cancer

Updated USPSTF Guidelines for Colorectal Cancer Screening: More Methods, More Challenges for Patients and Providers Alike

As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...

Colorectal Cancer

New USPSTF Recommendations for Colorectal Cancer Screening

As reported in JAMA, the U.S. Preventive Services Task Force ­(USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...

colorectal cancer

Joint Presence of Metabolic Syndrome and Obesity Seems to Be Associated With Poorer Survival in Early-Stage Colorectal Cancer

In a study in Kaiser Permanante patients reported in the Journal of Clinical Oncology, Cespedes Feliciano et al found that the joint presence of obesity and metabolic syndrome in those with early-stage colorectal cancer was associated with poorer overall and colorectal cancer–specific...

colorectal cancer

NCI Colorectal Cancer Risk Assessment Tool Estimates Current Risk of Advanced Neoplasia

In a study reported in the Journal of the National Cancer Institute, Imperiale et al found that the National Cancer Institute (NCI) colorectal cancer risk assessment tool was able to estimate the current risk for advanced colorectal neoplasia. Study Details The study involved 4,457 persons aged...

colorectal cancer

Better Overall Survival Reported With FOLFIRI Plus Cetuximab vs Plus Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer

In a post hoc analysis of the German phase III FIRE-3 trial reported in The Lancet Oncology, Stintzing et al found that first-line FOLFIRI (fluorouracil, leucovorin, irinotecan) plus cetuximab (Erbitux) was associated with improved overall survival vs FOLFIRI plus bevacizumab (Avastin) in an...

colorectal cancer

Tumor-Infiltrating Lymphocytes and Crohn’s-Like Lymphoid Reaction May Be Prognostic Indicators for Colorectal Cancer

Intratumoral tumor-infiltrating lymphocyte level and prominent peritumoral Crohn’s-like lymphoid reaction appear to be independent prognostic factors for survival in colorectal cancer, according to a study reported by Rozek et al in the Journal of the National Cancer Institute. The findings...

colorectal cancer

Retinoic Acid May Suppress Colorectal Cancer Development

Retinoic acid may play a critical role in suppressing colorectal cancer in mice and humans, according to researchers at the Stanford University School of Medicine. Mice with the cancer have lower-than-normal levels of the metabolite in their gut, the researchers found. Furthermore, colorectal...

Colorectal Cancer

ESMO Releases New Consensus Guidelines on the Management of Metastatic Colorectal Cancer

The European Society for Medical Oncology (ESMO) has released new consensus guidelines for the management of metastatic colorectal cancer that reflect an increasingly personalized approach to treatment. These guidelines were published by Van Cutsem et al in Annals of Oncology.1 “Management of...

Colorectal Cancer

Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making

Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...

Colorectal Cancer

Multiple Means to Realize the Benefits of Colorectal Cancer Screening

In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults aged 50 through 75; but rather than emphasize specific screening strategies, it notes there are multiple screening...

Colorectal Cancer

Anti–Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly Over Placebo in Advanced Colorectal Cancer

A novel anti–interleukin-1 alpha (IL-1α) antibody has shown a significant impact on symptoms and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented by Hickish et al at the European Society for Medical Oncology’s 18th World...

Colorectal Cancer

Anti–PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination With MEK Inhibition

Anti–PD-L1 (programmed death ligand 1) immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the European Society for Medical Oncology (ESMO) 18th World Congress on...

colorectal cancer

No Improvement in Outcome Reported With Longer Wait Between Radiochemotherapy and Surgery in Rectal Cancer

Pathologic complete response rate was not improved by increasing the interval between neoadjuvant chemoradiotherapy and surgery from 7 to 11 weeks in patients with rectal cancer, according to the French phase III GRECCAR-6 trial reported by Lefevre et al in the Journal of Clinical Oncology. In...

colorectal cancer

Gene-Expression Signature Assay Identifies High-Risk Stage II Colon Cancer

In an analysis reported in the Journal of Clinical Oncology, Niedzwiecki et al found that the ColDx gene-expression signature assay identified high-risk stage II colon cancer among patients in the phase III Alliance C9581 trial. This assay has been shown to be independently prognostic for...

Advertisement

Advertisement



Advertisement